Basic Spironolactone Information

• INN (International Nonproprietary Name): Spironolactone
• Brand Names Available In United Kingdom: Aldactide (listed in RAW DATA as available in UK); Aldactone (listed for multiple countries including Ireland but not explicitly UK in RAW DATA); Osyrol; Spiroctan; Spiretic; Uractone; Verospiron; Spiresis; Xenalon — packaging generally tablets 25 mg, 50 mg, 100 mg; combo products observed as Aldactide (with hydroflumethiazide) in RAW DATA.
• ATC Code: C03DA01
• Forms & Dosages: Tablets 25 mg, 50 mg, 100 mg; oral suspension (less common, sometimes compounded by pharmacies); combo tablets with hydrochlorothiazide (e.g., 25 mg/25 mg, 50 mg/50 mg).
• Manufacturers In United Kingdom: Pfizer (global supplier listed in RAW DATA); other UK-specific manufacturers not specified in RAW DATA.
• Registration Status In United Kingdom: Not specified in RAW DATA.
• OTC / Rx Classification: Prescription Only ("Rx") in nearly all jurisdictions per RAW DATA.

Latest Research Highlights (UK & EU 2022–2025)

Patients and prescribers ask whether spironolactone still has a clear role in heart failure and resistant hypertension.

Recent UK and EU analyses from 2022–2025 reinforce spironolactone’s established benefit signals as an adjunct in heart failure with reduced ejection fraction and in resistant hypertension.

Meta-analyses and NHS audit data emphasise using lower effective doses to balance clinical benefit against the risk of hyperkalaemia and renal deterioration.

Small UK dermatology trials report measurable improvement in adult female acne and hirsutism after three to six months on off‑label regimens.

Comparative European work continues to favour eplerenone where anti‑androgenic hormonal effects are undesirable, but spironolactone remains the more cost‑effective choice on many NHS pathways.

Clinical trial and labelling dosing use ATC code C03DA01 and common tablet strengths of 25 mg, 50 mg and 100 mg.

Safety signals in recent audits are consistent: hyperkalaemia and worsening renal function are the main adverse events to watch.

Recommended clinical presentation for commissioners: a table summarising outcomes (mortality, hospitalisation, skin scores) and safety (hyperkalaemia rates, renal events), plus a note to review MHRA safety communications and Yellow Card reports for up‑to‑date signals.

Clinical Effectiveness In The UK

Many patients want to know how spironolactone performs in everyday NHS practice.

• Heart Failure: Used as adjunctive therapy, typical NHS dosing 12.5–50 mg/day with observed reductions in hospital readmissions when combined with guideline therapy.
• Oedematous States: Employed in cirrhosis and nephrotic syndrome, often titrated to 100 mg/day or higher under specialist review to control fluid retention.
• Resistant Hypertension: Added where blood pressure remains uncontrolled on multiple agents, commonly within 25–100 mg/day range.
• Dermatology (Off‑Label): Adult female acne and hirsutism show cosmetic improvement after three to six months; typical off‑label dose range 50–200 mg/day as used in UK clinics.

Patient‑reported challenges seen on forums include dizziness, breast tenderness or gynecomastia, and the burden of regular blood tests for potassium and creatinine.

Indications & Expanded Uses (MHRA Versus NHS Practice)

Patients often ask what spironolactone is licensed for and what prescribers commonly use it for off‑label.

Oedema (Congestive Heart Failure, Cirrhosis, Nephrotic Syndrome)

Typical Dose: ~100 mg/day (range 25–200 mg/day). Monitoring: baseline potassium and creatinine, early follow‑up at 1–2 weeks.

Refractory Hypertension (Adjunct)

Typical Dose: 25–100 mg/day. Monitoring: regular blood tests, more frequently when combined with ACE inhibitors or ARBs.

Primary Hyperaldosteronism (Specialist)

Typical Dose: 100–400 mg/day for diagnostic or management purposes; specialist supervision required.

Female‑Pattern Acne and Hirsutism (Off‑Label)

Typical Dose: 50–200 mg/day. Monitoring: baseline and periodic potassium/renal checks; contraceptive discussion in women of childbearing age.

Pediatric Use

Used only in specialist paediatric settings with doses approximately 1–3 mg/kg/day divided.

Composition & Brand Landscape

Patients ask which brands and strengths they will see in the pharmacy.

ATC Classification: C03DA01, a potassium‑sparing aldosterone antagonist.

NHS procurement tends to favour cost‑effective generics, though older patients may recognise branded Aldactone packaging.

Pharmacies can compound oral suspensions if needed for patients unable to swallow tablets.

Contraindications & Special Precautions

Patients worry about who should not take spironolactone and what to check before starting.

• Absolute Contraindications: Acute renal insufficiency, anuria, Addison’s disease, known hypersensitivity, pre‑existing hyperkalaemia.
• Relative Contraindications: Renal impairment (exercise caution if CrCl <30 mL/min), hepatic dysfunction, pregnancy and lactation, elderly patients, diabetics with nephropathy.
• Practical Baseline Tests: Serum creatinine and potassium prior to initiation and within 1–2 weeks of starting or dose changes.

Red Flags For Prescribers

Rapidly rising potassium, oliguria/anuria, unexplained severe hypotension, signs of adrenal insufficiency — stop drug and seek urgent review.

Lifestyle Cautions

Drowsiness and dizziness may affect driving; avoid excessive alcohol; avoid potassium supplements or salt substitutes unless advised.

Dosage Guidelines (NHS Recommended Regimens & Adjustments)

People commonly ask how to start and adjust spironolactone safely.

For hepatic disease, use caution and monitor for encephalopathy in cirrhotic patients.

Interactions Overview (Drugs, Food, Yellow Card Signals)

Patients frequently ask which medicines to avoid while taking spironolactone.

• Pharmacists and GPs should alert patients when new prescriptions could increase potassium.
• Review all OTC NSAIDs and herbal supplements before dispensing spironolactone.

Cultural Perceptions & Patient Habits

People often ask where others turn for advice about spironolactone.

• Patients commonly discuss spironolactone on forums such as Patient.info and Mumsnet and value practical experience shared there.
• There is strong trust in community pharmacists and NHS clinicians for medication advice, with chains like Boots, LloydsPharmacy and Superdrug providing face‑to‑face counselling.
• Women using spironolactone for acne or hirsutism worry about hormonal side effects and fertility; shared decision‑making and clear monitoring plans improve adherence.
• The rise of online pharmacies and electronic prescriptions has improved access, but also increases queries about legitimacy and who arranges monitoring.

Case vignette: A 28‑year‑old woman starts 100 mg/day for acne with contraceptive counselling and arranged blood tests at 2 weeks, improving adherence and safety.

Pharmacist counselling prompts: confirm current medicines, advise blood‑test schedule, and explain signs of hyperkalaemia and when to seek urgent care.

Availability & Pricing Patterns (Boots, LloydsPharmacy, NHS Versus Private)

Patients ask where they can collect spironolactone and what it will cost.

Spironolactone is prescription‑only and widely stocked at high‑street pharmacies including Boots, LloydsPharmacy and Superdrug and at hospital pharmacies.

The NHS typically prescribes generics, while branded Aldactone may still appear in secondary care or legacy supplies.

In England patients typically pay the NHS prescription charge unless exempt; prescriptions are free in Scotland, Wales and Northern Ireland, creating regional cost differences.

Private clinic prescriptions for acne may incur out‑of‑pocket costs for the drug and for blood‑test monitoring.

In our online pharmacy, spironolactone is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Prescribing Preferences

Clinicians and patients compare spironolactone with alternatives when choosing therapy.

FAQ — Common NHS Patient Questions

• Can I get spironolactone on the NHS?

  Yes, with a prescription; generics are commonly prescribed and monitoring is usually arranged by your GP or specialist.

• Will it cause breast enlargement or impotence?

  Hormonal effects such as breast tenderness or gynecomastia and rare sexual dysfunction can occur; report persistent symptoms to your prescriber and consider switching to eplerenone if needed.

• What monitoring is needed?

  Baseline and early follow‑up blood tests for potassium and creatinine (typically within 1–2 weeks), then periodic checks depending on risk factors and co‑medications.

• Can I take potassium supplements or salt substitutes?

  Avoid additional potassium unless advised by a clinician; combining supplements or salt substitutes with spironolactone can cause dangerous hyperkalaemia.

Guidelines For Proper Use (Pharmacist Counselling & NHS Patient Advice)

Pharmacists ask what to tell patients when handing out spironolactone.

• Confirm the indication and review current medicines for interactions before supply.
• Advise baseline blood tests (renal function and potassium) and early follow‑up at 1–2 weeks after initiation or dose change.
• Explain common side effects: gastrointestinal upset, dizziness, drowsiness, breast changes, and signs of hyperkalaemia such as muscle weakness or palpitations.
• Missed Dose Advice: Take when remembered unless close to the next dose; do not double dose.
• Overdose Advice: Severe symptoms such as profound drowsiness, confusion or signs of hyperkalaemia require emergency care—advise attendance at A&E immediately.
• Storage: Store at 20–25°C, protect from moisture, keep in original packaging.
• Reproductive Advice: Patients planning pregnancy should discuss plans with prescriber; use effective contraception if on off‑label treatment for acne.

Provide patients with a one‑page leaflet showing a monitoring timetable: baseline tests, 1–2 week check, one month, then periodic reviews every 3–6 months depending on stability.

Delivery Across United Kingdom